Novo Nordisk's Rybelsus Receives EU Approval for Heart Benefits in Diabetes

Novo Nordisk's Rybelsus has been approved by the EU for cardiovascular benefits in diabetes patients, making it the first oral GLP-1 receptor agonist in the EU with proven cardiovascular benefit. This adds to Novo Nordisk's evidence base for oral GLP-1 and reinforces a key short-term catalyst, but does not directly address near-term pricing pressures in the US. The company has updated its guidance for 2025, lowering expected operating profit growth.